Genetic Technologies Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Kevin Camilleri

Algemeen directeur

AU$296.1k

Totale compensatie

Percentage CEO-salaris	87.0%
Dienstverband CEO	3.3yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	3.3yrs
Gemiddelde ambtstermijn bestuur	4.9yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Kevin Camilleri's beloning veranderd ten opzichte van Genetic Technologies's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	AU$296k	AU$258k	-AU$12m
Mar 31 2024	n/a	n/a	-AU$12m
Dec 31 2023	n/a	n/a	-AU$13m
Sep 30 2023	n/a	n/a	-AU$12m
Jun 30 2023	AU$281k	AU$233k	-AU$12m
Mar 31 2023	n/a	n/a	-AU$10m
Dec 31 2022	n/a	n/a	-AU$9m
Sep 30 2022	n/a	n/a	-AU$8m
Jun 30 2022	AU$285k	AU$212k	-AU$7m

Compensatie versus markt: De totale vergoeding ($USD 192.26K ) Kevin } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 298.27K ).

Compensatie versus inkomsten: De vergoeding van Kevin is gestegen terwijl het bedrijf verliesgevend is.

CEO

Kevin Camilleri (47 yo)

3.3yrs

Tenure

AU$296,120

Compensatie

Mr. Kevin Camilleri serves as Chief Executive Officer of EasyDNA at Genetic Technologies Limited since August 16, 2021. Mr. Camilleri joined the Genetic Technologies Limited in 2021. He has been Chief Oper...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Kevin Camilleri	Chief Executive Officer of EasyDNA	3.3yrs	AU$296.12k	geen gegevens
Mark Ziirsen	CFO & Company Secretary	less than a year	geen gegevens	geen gegevens
Paul Keith Viney	Consultant	5.3yrs	AU$180.45k	geen gegevens
Erika Spaeth	Director of Clinical & Scientific Affairs	no data	geen gegevens	geen gegevens

3.3yrs

Gemiddelde duur

Ervaren management: Het managementteam van GTG wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Lindsay Wakefield	Independent Non-Executive Director	10.2yrs	AU$74.88k	0.065% A$ 3.7k
Peter Rubinstein	Independent Non-Executive Chairman	6.8yrs	AU$150.19k	2.54% A$ 144.2k
Jerzy Muchnicki	Non-Independent Non-Executive Director	6.8yrs	AU$87.44k	1.55% A$ 87.8k
Finlay Macrae	Member of Scientific & Medical Advisory Board	3yrs	geen gegevens	geen gegevens
Jon Emery	Member of Scientific & Medical Advisory Board	3yrs	geen gegevens	geen gegevens
Ora Gordon	Member of Scientific & Medical Advisory Board	3yrs	geen gegevens	geen gegevens

4.9yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van GTG wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.9 jaar).

Genetic Technologies Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Genetic Technologies Limited Appoints Mark Ziirsen as Chief Financial Officer

Genetic Technologies Limited Announces Resignation of Kathryn Andrews as CFO

Independent Non-Executive Chairman recently bought AU$80k worth of stock

Genetic Technologies Limited Announces Resignation of Tony Di Pietro as Chief Financial Officer

Genetic Technologies Limited, Annual General Meeting, Nov 22, 2023

Non-Independent Non-Executive Director recently sold AU$77k worth of stock

Recent updates

Full year 2024 earnings released: AU$0.091 loss per share (vs AU$0.12 loss in FY 2023)

Genetic Technologies Limited Announces Global Launch of GeneType on Wholly Owned EasyDNA Platform

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of AUD 1.71026 million.

Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of AUD 3.997793 million.

Genetic Technologies Limited Appoints Mark Ziirsen as Chief Financial Officer

Genetic Technologies Limited Announces Resignation of Kathryn Andrews as CFO

Genetic Technologies Limited Share the Power of the geneType Test in Identifying Risk and Improving the Health of Populations Worldwide

New major risk - Revenue and earnings growth

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of $2 million.

New minor risk - Shareholder dilution

Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of $11.2056 million.

Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of $2 million.

Genetic Technologies Limited Establishes Clinical Implementation Study with Breast Screen Centres Across New York, Miami and Houston

Genetic Technologies Limited to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare

Independent Non-Executive Chairman recently bought AU$80k worth of stock

New major risk - Financial position

Genetic Technologies Limited Announces Resignation of Tony Di Pietro as Chief Financial Officer

Genetic Technologies Regains Compliance with Nasdaq Minimum Bid Price Requirement

New major risk - Market cap size

Genetic Technologies Limited, Annual General Meeting, Nov 22, 2023

Genetic Technologies Limited Announces the Expanded GeneType Multi-Risk Test Is Now Available to Order in Australia

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2022)

New minor risk - Financial data availability

First half 2023 earnings released: AU$0.001 loss per share (vs AU$0 in 1H 2022)

Genetic Technologies Limited Announces Publication Highlights Genetype’S Ability to Detect Breast Cancer Earlier and Provide Data for Risk Stratification

Genetic Technologies Limited Provides Further Update on Comprehensive Risk Test for Breast & Ovarian Cancer

Genetic Technologies Limited to Launch World’s First Comprehensive Risk Test for Breast & Ovarian Cancer

Non-Independent Non-Executive Director recently sold AU$77k worth of stock

Genetic Technologies Limited Published in Plus One for Cvd & Type 2 Diabetes

Genetic Technologies Limited, Annual General Meeting, Nov 28, 2022

Genetic Technologies Limited Appoints Tony Di Pietro as Chief Financial Officer

Full year 2022 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2021)

Genetic Technologies Limited (ASX:GTG) completed the acquisition of eCommerce Business and Distribution Rights of AffinityDNA from Affinity DNA Limited.

Genetic Technologies Limited Announces Resignation of Michael Tonroe as Company Secretary

Genetic Technologies Limited Commences Initial Implementation of its geneType Risk Assessment Test at 16 Medical Practices Across the East Coast of Australia

Genetic Technologies Limited Announces the Completion of an Independently Developed and Validated Customisable Budget Impact Model

Genetic Technologies Limited (ASX:GTG) entered into an agreement to acquire eCommerce Business and Distribution Rights of AffinityDNA from Affinity Dna Limited for £0.555 million

Genetic Technologies Limited Announces GeneType Multi-Test Approves for Commercial Release

High number of new and inexperienced directors

Full year 2021 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2020)

Genetic Technologies Limited (ASX:GTG) completed the acquisition of General Genetics Corporation from BelHealth Investment Fund, L.P. managed by BelHealth Investment Partners, LLC.

Company Secretary Justyn Stedwell has left the company

Genetic Technologies Limited Confirms the Launch of GTG's Covid-19 Serious Disease Risk Test (`Covid-19 Risk Test') by US Based Infinity Biologix LLC

Genetic Technologies Limited Provides COVID-19 Risk Test Launch Update

Genetic Technologies Limited Signs 3-Year US Licence Agreement for COVID Risk Test

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of $6.5625 million.

Genetic Technologies Limited Provides Update on Its COVID-19 Disease Severity Risk Test and Expansion into Germline Testing

Genetic Technologies Limited Announces Management Changes

Genetic Technologies Secures US and ANZ Distribution Rights for PREDICTIX

Genetic Technologies Limited, Annual General Meeting, Dec 10, 2020

Genetic Technologies Limited to Report Q4, 2020 Results on Oct 30, 2020

Full year earnings released - AU$0.0015 loss per share

Genetic Technologies Provides Update on COVID-19 Risk Test

Full year earnings released - AU$0.0015 loss per share

Full year earnings released - AU$0.0015 loss per share

Genetic Technologies Regains Compliance with Nasdaq Stockholders Equity Requirement

Full year earnings released - AU$0.0015 loss per share

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of $5.125 million.

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd